Antemortem biomarker support for a diagnosis of clinically probable chronic traumatic encephalopathy

A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies

“…The different performances of [ 18 F]flortaucipir in AD and non-AD tauopathies could also be linked to the different size and ultrastructural conformations of the respective twisted or straight tau filaments [161]. As for tau-PET in CTE, postmortem tissue autoradiography studies are still lacking, but they are essential for potential inclusion of tau-PET in the CTE diagnostic workup [162]. As for in vivo [ 18 F]flortaucipir binding in svPPA [44,45], it should be taken into account that postmortem brain tissue evaluation demonstrates null or weak binding of this tracer to TDP-43 aggregates in pathologically verified FTLD-TDP cases [140,141,163].…”

Military‐related risk factors for dementia

“…Tau PET tracers may also be useful as progression biomarkers for tauopathies, and for distinguishing the tauopathy of AD from others (127). Such patterns are beginning to emerge with further experience with tau tracers, matching patterns of tau PET ligand retention with known neuropathological distribution (128). However, the currently available tau PET imaging of Vietnam War veterans with TBI and/or PTSD studied in the ADNI-DoD study suggests that there may be significant variability between individuals while not much group variation.…”